the aid library

LIST OPTIONS

Filter

5475

External Link

Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study

L. R. Augustemak de Lima; E. L. Petroski; Y. M. F. Moreno; et al. PLOS ONE (2018) CC

Research Article PLOS ONE | https://doi.org/10.1371/journal.pone.0190785 January 10, 2018

External Link

A comparative analysis of national HIV policies in six African countries with generalized epidemics

K. Church; F. Kiweewa, A.Dasgupta; et al. Bull World Health Organ; PMC (US National Library of Medicine National Institutes of Health) (2015) C2

Bull World Health Organ 2015;93:457–467 | doi: http://dx.doi.org/10.2471/BLT.14.147215

Download (554)

View PDF (398)

Management of Diabetes Mellitus-Tuberculosis
recommended

Lin, Y., et al. The Union (2019) C1

1st edition This resource provides practical guidance for front line health workers responsible for the diagnosis, management and care of patients with these two diseases. Published in collaboration with the World Diabetes Foundation

Download (383)

View PDF (648)

Uganda: Maama Kit - Making childbirth clean and safer

WHO, Ministry of Health Uganda (2006) C_WHO

External Link

Antimicrobial Resistance: Challenges and Perspectives

Doyle, M.P.; G. H. Loneragan, H. M. Scott et al. (2006) C2

Comprehensive Reviews in Food Science and Food Safety, Vol.12 (2013) pp.234-248 In 2006, the Institute of Food Technologists (IFT) published an Expert Report entitled “Antimicrobial Resistance: Implications for the Food System” (IFT 2006). That report summarized current scientiﬁc knowledge pe... more

Download (479)

View PDF (608)

Venezuela´s humanitarian crisis. Severe Medical and Food Shortages, Inadequate and Repressive Government Response

Human Rights Watch (2016) C1

Download (551)

View PDF (799)

National Guidelines for Quality Improvement of HIV and AIDS Services

Ministry of Health and Social Welfare, National AIDS Control Programme, Tanzania (2010) C1

External Link

Trachoma Action Planning TAP

International Coalition for Trachoma Control ICTC (2022) CC

In 2011, ICTC developed a Trachoma Action Plan (TAP) planning guide to support national health officials in endemic countries. This resource was developed to complement the 2020 INSight roadmap by helping countries create specific national plans detailing how they will reach elimination targets in t... more

External Link

Policy Snapshot: Cholesterol Control and Management in Brazil

World Heart Federation (2015) CC

Worldwide, there are about 17 million deaths due to cardiovascular disease (CVD) each year and at least two or three times as many non-fatal events. Raised cholesterol greatly increases the risks of stroke and heart disease, causing a large health burden across the world. The World Health Organizat... more

External Link

Guideline on when to start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

Elaine Abrams, Tsitsi Apollo, Janet Bhila et al. World Health Organization WHO (2015) C_WHO

The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ... more

External Link

Standard Treatment Guidelines and Essential Medicines List of Common Medical Conditions

Government of the Kingdom of Swaziland Ministry of Health (2012) C2

The product of all this work is the Standard Treatment Guideline and Essential Medicines List of Common Medical Conditions in the Kingdom of Swaziland. These systematically developed statements are designed to assist practitioners in making decisions about appropriate treatment for specific clinical... more

Download (376)

View PDF (793)

Water sanitation and hygiene for accelerating and sustaining progress on neglected tropical diseases: A global strategy 2015-2020

World Health Organization (WHO) (2015) C_WHO

Water, sanitation and hygiene (WASH) are critical in the prevention and care for all of the 17 neglected tropical diseases (NTDs) scheduled for intensified control or elimination by 2020.
Provision of safe water, sanitation and hygiene is one of the five key interventions within the global NTD ... more

Download (160)

View PDF (184)

The Global State of Harm Reduction 2016

K. Stone; G. Sander Harm Reduction International (2016) C2

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more